[
  {
    "ts": null,
    "headline": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
    "summary": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
    "url": "https://finnhub.io/api/news?id=642997139796d1ec22e42b910d04d46a39c8d9d41e0d602b85609a2eb28d3a9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747342160,
      "headline": "Does Anavex's Alzheimer's Drug Actually Confer Benefit?",
      "id": 134486300,
      "image": "",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=642997139796d1ec22e42b910d04d46a39c8d9d41e0d602b85609a2eb28d3a9d"
    }
  },
  {
    "ts": null,
    "headline": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
    "summary": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
    "url": "https://finnhub.io/api/news?id=b756f83ede5a952ac1cd88a2f2bfbfaeb147a2d8042368572bb7e00b02603f9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747330084,
      "headline": "INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity",
      "id": 134485546,
      "image": "",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b756f83ede5a952ac1cd88a2f2bfbfaeb147a2d8042368572bb7e00b02603f9d"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
    "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=fbb04b5a59dbbd579af6599e5a7a1254b2f21d16d3b9c3b2fd4a8436f60fcf56",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747329000,
      "headline": "Biogen Inc. stock outperforms competitors on strong trading day",
      "id": 134547359,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=fbb04b5a59dbbd579af6599e5a7a1254b2f21d16d3b9c3b2fd4a8436f60fcf56"
    }
  },
  {
    "ts": null,
    "headline": "BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=45495cdaf5c7dee7c96664176ebc3fb03fe8f183ee8c69c321869c93b4170d81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747318697,
      "headline": "BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance",
      "id": 134484015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=45495cdaf5c7dee7c96664176ebc3fb03fe8f183ee8c69c321869c93b4170d81"
    }
  }
]